Menu
Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ
Keywords
Last Name
Institution
@uada.edu
@ualr.edu
@uapb.edu
@uark.edu
University of Arkansas for Medical Sciences
More Search Options
Announcement
You can now add alternative names!
Click here
to add other names that you've published under.
Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med. 2006 Oct; 160(10):1070-6.
View in:
PubMed
subject areas
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antiviral Agents
Asthma
Comorbidity
Cost of Illness
Cost-Benefit Analysis
Decision Support Techniques
Gestational Age
Humans
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases
Length of Stay
Quality-Adjusted Life Years
Respiratory Syncytial Virus Infections
authors with profiles
Nahed El-Hassan